Friday, July 10, 2026

pharma · Atopic Dermatitis · COVID-19

Qilu Pharmaceuticals

Qilu Pharmaceuticals clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
1958 Founded
243 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Founded
1958
Employees
243
Programs
2
Drugs
4
Patents
0
Intelligence · Clinical Programs

Qilu Pharmaceuticals projects

2 ClinicalTrials.gov programs sponsored by Qilu Pharmaceuticals.

Qilu Pharmaceuticals has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. QL2108 injection

    Qilu Pharmaceutical (Hainan) Co.,

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial
  2. QLS1128 A-Dose 1~5 and Ritonavir

    Qilu Pharmaceutical (Hainan) Co.,

    COVID-19

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Qilu Pharmaceuticals have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.